Label: SOLUVIT N- thiamine mononitrate, riboflavin 5-phosphate sodium anhydrous, niacinamide, pyridoxine hydrochloride, folic acid, cyanocobalamin, sodium pantothenate, biotin, sodium ascorbate powder, for solution

  • NDC Code(s): 65219-077-15
  • Packager: Fresenius Kabi USA, LLC
  • Category: HUMAN PRESCRIPTION DRUG LABEL
  • DEA Schedule: None
  • Marketing Status: Export only

Drug Label Information

Updated July 7, 2023

If you are a consumer or patient please visit this version.

  • Presentation

    Soluvit N is a lyophilized, sterile, yellow mixture of water soluble vitamins for intravenous infusion. Qualitative and Quantitative Composition

  • ACTIVE INGREDIENT

    One vial of Soluvit N contains:

    Active ingredientsQuantity1 ml of reconstituted
    Thiamine Soluvit N contains:
    mononitrate (Corresponding to Vitamin B1 2.5 mg)
    Riboflavine sodium
    3.1 mg 0.31 mg
    phosphate (Corresponding to
    Vitamin B2 3.6 mg)
    4.9 mg 0.49 mg
    Nicotinamide
    Pyridoxine
    40 mg 4.0 mg
    hydrochloride (corresponding to Vitamin B6 4.0 mg)
    Sodium
    4.9 mg 0.49 mg
    pantothenate (corresponding to pantothenic acid
    15.0 mg)
    16.5 mg 1.65 mg

    Sodium ascorbate
    (corresponding to
    Vitamin C 100 mg)

    113 mg

    11.3 mg
    Biotin 60 μg 6.0 μg
    Folic acid 0.40 mg 40 μg
    Cyanocobalamin 5.0 μg 0.5 μg

    For the full list of excipients, see section list of excipients.

    • Osmolality in 10 ml of water: approx. 490 mosm/kg water
    • pH in 10 ml of water: 5.8

    Therapeutic indications

    Soluvit N is indicated in adult patients and children as a supplement in intravenous nutrition to meet the daily requirements of water soluble vitamins.

  • Posology and method of administration

    Posology

    Adults:

    For adult patients and children weighing 10 kg or more, the recommended daily dosage is the content of one vial.

    Infants:

    Children weighing less than 10 kg should be given 1/10 of the content of one vial per kg body weight per day.

  • Contraindications

    Known hypersensitivity to any of the components, e.g. thiamine or methyl parahydroxybenzoate.

  • Special warning and special precaution for use

    Soluvit N must not be given undiluted.

    When Soluvit N is diluted with water based solutions, the admixture should be protected from light. This is not necessary if Soluvit N is diluted with Intralipid because of the protective effect of the fat emulsion.

    Interference with clinical laboratory tests

    Biotin may interfere with laboratory tests that are based on a biotin/streptavidin interaction, leading to either falsely decreased or falsely increased test results, depending on the assay. The risk of interference is higher in children and patients with renal impairment and increases with higher doses. When interpreting results of laboratory tests, possible biotin interference has to be taken into consideration, especially if a lack of coherence with the clinical presentation is observed (e.g. thyroid test results mimicking Graves' disease in asymptomatic patients taking biotin or false negative troponin test results in patients with myocardial infarction taking biotin). Alternative tests not susceptible to biotin interference should be used, if available, in cases where interference is suspected. The laboratory personnel should be consulted when ordering laboratory tests in patients taking biotin.

  • Interaction with other medicinal products and other forms of interaction

    Folic acid may lower the serum concentration of phenytoin and obscure pernicious anaemia.

    Vitamin B6 can reduce the effect of levodopa.

  • Fertility, pregnancy and lactation

    Animal reproduction studies or clinical investigations during pregnancy have not been carried out with Soluvit N. There are, however, published reports on safe administration of water soluble vitamins in this patient group.

  • Effects on ability to drive and use machines

    Not relevant.

  • Undesirable effects

    Allergic reactions including severe (anaphylactic) reactions may occur in patients hypersensitive to any component of the preparation, e.g. folic acid, thiamine or methyl parahydroxybensoate (frequency not known).

    Reporting of suspected adverse reactions

    Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system.

  • Overdose

    No adverse effects of an overdose of water soluble vitamins have been reported, with exception of cases of extremly high parenteral doses. Overdoses caused by parenteral preparations for nutritional supplement of water soluble vitamins have not been reported.

    No specific treatment is needed. See also section Contraindications.

  • List of excipients

    Glycine (Aminoacetic acid)

    Disodium edetate.

    Methyl parahydroxybenzoate

  • Incompatibilities

    Soluvit N may only be added to or mixed with other medicinal products for which compatibility has been documented.

  • Shelf-life of the medicinal product as packed for sale

    18 months

    Shelf-life after mixing

    Chemical and physical in-use stability after dilution has been demonstrated for 24 hours at 25°C. From a microbiological point of view, the product should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2-8°C, unless mixing has taken place in controlled and validated aseptic conditions.

  • Special precautions for storage

    Do not store above 25°C. Protect from light.

  • Instructions for use/handling, and disposal

    Adults and children age 11 years and above:

    The contents of one vial of Soluvit N are dissolved by adding 10 ml of:

    1. Vitalipid N Adult

    or 2. Intralipid 10%, Intralipid 20%, Intralipid 30%, Structolipid

    or 3. Water for Injections

    or 4. Glucose solution for infusion (5%-50%)

    Soluvit N may be added to parenteral nutrition admixtures containing carbohydrates, lipids, amino acids, electrolytes and trace elements provided that compatibility and stability have been confirmed.

    Children below 11 years of age:

    The contents of one vial are dissolved by adding 10 ml of:

    1. Vitalipid N Infant (for children above 10 kg/bw)

    or 2. Intralipid 10%, Intralipid 20%

    or 3. Water for Injections

    or 4. Glucose solution for infusion (5%-50%)

    Children weighing less than 10 kg should be given 1 ml of the dissolved mixture per kg body weight per day. Children weighing 10 kg or more should be given 10 ml (one vial) per day.

    Due to differences in the dosage regimes for Soluvit N and Vitalipid N Infant, the mixture 1 is not recommended for children weighing less than 10 kg.

    Soluvit N may be added to parenteral nutrition admixtures containing carbohydrates, lipids, amino acids, electrolytes and trace elements provided that compatibility and stability have been confirmed.

    Disposal

    Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

    Manufacturer:

    Fresenius Kabi AB, Uppsala, Sweden

    March 2019

    Fresenius Kabi Logo

  • PRINCIPAL DISPLAY PANEL

    PACKAGE LABEL – PRINCIPAL DISPLAY – Soluvit N Vial Label

    Soluvit N

    Powder for solution for infusion

    PACKAGE LABEL – PRINCIPAL DISPLAY – Soluvit N Vial Label
  • PRINCIPAL DISPLAY PANEL

    PACKAGE LABEL – PRINCIPAL DISPLAY – Soluvit N Carton

    Soluvit™ N

    Powder for solution for infusion

    10 Vials

    PACKAGE LABEL – PRINCIPAL DISPLAY – Soluvit N Carton
  • INGREDIENTS AND APPEARANCE
    SOLUVIT N 
    thiamine mononitrate, riboflavin 5-phosphate sodium anhydrous, niacinamide, pyridoxine hydrochloride, folic acid, cyanocobalamin, sodium pantothenate, biotin, sodium ascorbate powder, for solution
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC:65219-077
    Route of AdministrationINTRAVENOUS
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    thiamine mononitrate (UNII: 8K0I04919X) (thiamine ion - UNII:4ABT0J945J) THIAMINE1.581 mg  in 1 mL
    riboflavin 5'-phosphate sodium anhydrous (UNII: 957E53WV42) (riboflavin 5'-phosphate - UNII:7N464URE7E) riboflavin 5'-phosphate2.45 mg  in 1 mL
    niacinamide (UNII: 25X51I8RD4) (niacinamide - UNII:25X51I8RD4) niacinamide20.0 mg  in 1 mL
    pyridoxine hydrochloride (UNII: 68Y4CF58BV) (pyridoxine - UNII:KV2JZ1BI6Z) pyridoxine hydrochloride2.45 mg  in 1 mL
    folic acid (UNII: 935E97BOY8) (folic acid - UNII:935E97BOY8) folic acid0.216 mg  in 1 mL
    cyanocobalamin (UNII: P6YC3EG204) (cyanocobalamin - UNII:P6YC3EG204) cyanocobalamin2.775 ug  in 1 mL
    sodium pantothenate (UNII: OES0R93F0C) (pantothenic acid - UNII:19F5HK2737) sodium pantothenate8.25 mg  in 1 mL
    biotin (UNII: 6SO6U10H04) (biotin - UNII:6SO6U10H04) biotin30.0 ug  in 1 mL
    sodium ascorbate (UNII: S033EH8359) (ascorbic acid - UNII:PQ6CK8PD0R) ascorbic acid56.5 mg  in 1 mL
    Inactive Ingredients
    Ingredient NameStrength
    edetate disodium (UNII: 7FLD91C86K)  
    glycine (UNII: TE7660XO1C)  
    water (UNII: 059QF0KO0R)  
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC:65219-077-1510 in 1 CARTON07/07/2023
    12 mL in 1 VIAL; Type 0: Not a Combination Product
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    Export only07/07/2023
    Labeler - Fresenius Kabi USA, LLC (013547657)
    Establishment
    NameAddressID/FEIBusiness Operations
    Fresenius Kabi USA, LLC840771732ANALYSIS(65219-077) , MANUFACTURE(65219-077)